logo-loader
PreveCeutical Medical Inc

PreveCeutical says team has created 10-to-12 month plan aimed at concluding dual gene therapy R&D programme

The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth

The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
DNA strands

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) said its research team at the University of Queensland has created a 10-to-12 month plan aimed at successfully concluding the current phase of its dual gene therapy research and development programme.

The health sciences company - which is developing innovative options for preventive and curative therapies utilizing organic and nature identical products - noted that the plan was formulated at a recently held two-day intensive workshop.

READ: PreveCeutical Medical set for due diligence trip on Penta 5 acquisition

That workshop brought together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth to collaborate on the R&D programme, which is intended to address the increasing prevalence of obesity and diabetes using smart siRNA and tissue targeted bio-responsive delivery systems.

The company said the programme aim is to demonstrate proof-of-concept in the delivery of smart siRNAs - small interfering Ribonucleic Acid, a class of double-stranded RNA molecules - and effective in-cell modulation of a key biomarker implicated in diabetes and obesity.

It pointed out that the primary objectives of the workshop were to share key data derived to-date from gene engineering, delivery system design and synthesis and their evaluation in cellular models of diabetes and obesity.

The group said the teams assessed and resolved potential assay bottlenecks, paving the way for high throughput screening of smart siRNA candidate libraries, which is anticipated to expedite the programme's progress.

Once the current phase of the program is complete, PreveCeutical added, it will move to the final phase where the safety and efficacy of the primary smart siRNA-delivery system constructs will be evaluated in preclinical models of diabetes and obesity.

Quick facts: PreveCeutical Medical Inc

Price: $0.04

Market: CSE
Market Cap: $15.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 26/4/19

2 min read